Healthcare, Pharma & Life Sciences

Brookdale Senior Living Discloses August 2026 Occupancy Data

Image
Brookdale Senior Living Discloses August 2026 Occupancy Data

Brentwood, Tenn. – September 16, 2026 -- Brookdale Senior Living Inc. (NYSE: BKD) disclosed its occupancy performance for August 2026, covering a portfolio capable of serving approximately 45,000 residents.

Brookdale operates 532 senior living communities across 41 states as of September 16, 2026

The Brentwood, Tennessee-based operator confirmed its network size in the filing, spanning independent living, assisted living, memory care, and continuing care retirement communities. The company did not disclose specific occupancy percentage figures in the material reviewed for this report.

Brookdale shares trade on the NYSE under ticker BKD

The disclosure forms part of Brookdale's routine monthly reporting cadence to investors tracking senior housing demand trends.

Seismic Pharma Launches Phase 3 Trial for Cardiogenic Shock Drug

Durham – September 16, 2026 -- Seismic Pharmaceuticals has commenced a global Phase 3 trial of Istaroxime, aiming to deliver the first-ever approved drug for cardiogenic shock, a condition with no currently FDA-approved treatments.

Trial to enroll 600 patients across three continents

The study, named Rescue HF CS, will recruit approximately 600 patients at clinical sites in the United States, Europe and South America. It builds on four completed Phase 2 trials in which more than 340 patients received Istaroxime.

Dermatologist Zirvi Honored by Marquis Who's Who as Illumina IP Case Concludes

Image
Dermatologist Zirvi Honored by Marquis Who's Who as Illumina IP Case Concludes

Uniondale, N.Y. – September 16, 2026 -- Marquis Who's Who has included Monib A. Zirvi, MD, PhD, in its biographical volumes, recognizing more than two decades of work in dermatology and diagnostic genetics as a related patent dispute involving Illumina Inc. reaches final resolution.

Zirvi Has Practiced Dermatology at Summit Health Since 2004

Dr. Zirvi has served as a dermatologist with Summit Health and as an attending physician at Atlantic Health System's Overlook Medical Center since 2004, focusing on general dermatology, skin cancer detection and hair and nail disorders. Summit Health named him among its 2026 Castle Connolly Top Doctors. He is board certified by the American Board of Dermatology and holds a courtesy instructor appointment in microbiology and immunology at Weill Cornell Medicine, where he earned his MD and PhD.

Ambit RD Sold to Danforth Health in Avesi-Backed Life Sciences Deal

Image
Ambit RD Sold to Danforth Health in Avesi-Backed Life Sciences Deal

Washington – – September 16, 2026 -- Clearsight Advisors served as exclusive sell-side advisor to Ambit RD, Inc. on its acquisition by Danforth Health, Inc., a portfolio company of Avesi Partners, in a deal announced by the firms.

Ambit brings patient-identification technology to Danforth's life sciences platform

Ambit RD specializes in commercial strategy, advanced analytics, and patient identification solutions for rare and specialty biopharma markets, operating through three service lines: Strategic Services, Analytics & Data Services, and Patient ID Services. The company helps biopharmaceutical organizations locate patients, speed therapy adoption, and engage healthcare providers across the clinical and commercial continuum.

Fibryga Cuts Blood Transfusions 19% in Cardiac Surgery Subgroups

Image
Fibryga Cuts Blood Transfusions 19% in Cardiac Surgery Subgroups

Paramus, N.J. – – September 15, 2026 -- A prespecified secondary analysis of the landmark FIBRES trial found that Octapharma's fibryga (fibrinogen [human]) cut 24-hour allogeneic blood-product transfusion requirements by 19% versus cryoprecipitate in two overlapping patient subgroups, according to findings published in the Journal of Cardiothoracic and Vascular Anesthesia.

Non-critical and elective surgery patients showed the sharpest transfusion reductions

Among 634 patients classified as non-critical before surgery -- 86% of the primary trial population -- those receiving fibryga required 13.6 blood-product units on average versus 16.2 units for cryoprecipitate recipients, a 19% relative reduction. In the 466-patient elective-surgery subgroup, representing 63% of the primary population, fibryga patients received 11.7 units compared with 14.4 units for cryoprecipitate, matching the 19% relative reduction.

Partillion Bioscience Wins $2.1M NIH Grant for Cell-Cell-seq

Image
Partillion Bioscience Wins $2.1M NIH Grant for Cell-Cell-seq

Los Angeles – September 15, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award to scale its Cell-Cell-seq technology toward datasets of up to one million cell pairs. The grant, awarded by the National Institute of General Medical Sciences (NIGMS) under Award Number R44GM165220, is Partillion's 10th SBIR grant and brings the company's total non-dilutive federal funding past $8 million, roughly matching its private investment to date without additional equity dilution.

ARPA-H Awards UpDoc $9.2M to Build FDA-Track Autonomous Cardiac AI

Palo Alto, Calif. – September 15, 2026 -- UpDoc has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as lead performer in the Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program, securing an award of up to $9.2 million. Microsoft, OpenAI and NVIDIA are joining the UpDoc-led team as supporting partners.

Hyundai Launches $2M+ Pediatric Cancer Campaign With Scarlett Johansson

Image
Hyundai Launches $2M+ Pediatric Cancer Campaign With Scarlett Johansson

United States – September 15, 2026 -- Hyundai Motor America has committed more than $300 million to pediatric cancer research since 1998 through its Hope on Wheels program, a figure the automaker is now amplifying with a new national campaign, The Mark of a Warrior, timed to National Childhood Cancer Awareness Month in September.

Hyundai ties campaign launch to a diagnosis every 36 minutes

One child is diagnosed with cancer every 36 minutes in the United States, according to Hyundai, underscoring the urgency behind a 28-year fundraising effort that has supported research benefiting more than 40,000 children. The company, its dealer network and buyers of every new Hyundai fund the program.

Altesa's Vapendavir Cuts Inflammatory Markers in COPD Rhinovirus Study

Image
Altesa's Vapendavir Cuts Inflammatory Markers in COPD Rhinovirus Study

Barcelona, Spain – September 15, 2026 -- Altesa BioSciences reported that its investigational oral antiviral vapendavir significantly reduced two key inflammatory biomarkers, IP-10/CXCL10 and GM-CSF, in COPD patients experimentally infected with rhinovirus, according to data presented at the European Respiratory Society (ERS) International Congress 2026.

Vapendavir lowers airway inflammation markers in Phase 2a challenge study

Nasal lavage samples from COPD patients treated with vapendavir showed significantly lower levels of IP-10/CXCL10 and GM-CSF compared to placebo over the course of rhinovirus infection. Two additional biomarkers, IFN-α2a and IFN-λ1/IL-29, trended lower with treatment but did not reach statistical significance.

Cytonics Raises $4.8M, Hits 8,000 Investors for A2M Therapy

Image
Cytonics Raises $4.8M, Hits 8,000 Investors for A2M Therapy

Jupiter, Florida – September 15, 2026 -- Cytonics Corporation has closed a financing campaign generating $4.8 million in gross proceeds, pushing its total capital raised to $47 million and expanding its investor base to approximately 8,000 shareholders.

Cytonics attracts 900 new investors as 35% of existing shareholders reinvest

The clinical-stage biotechnology company completed approximately 1,500 individual investments in the round, including roughly 900 first-time backers. Of the pre-raise shareholder base, 35% chose to invest again, according to the company. The raise brings cumulative funds secured through Regulation A and Regulation Crowdfunding offerings to $27 million.